Dimethotrexate | 133073-73-1

• 物质功能分类: 原料药 - 抗肿瘤药 - 其它抗肿瘤药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: Dimethotrexate
• 英文别名: (2S)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid
• CAS: 133073-73-1
• 化学式: C40H44N16O10
• 分子量: 908.9
• InChiKey: FOBMAFJPPNVNEI-CHNGVTQJSA-N

物化性质

• 熔点：
  195 °C
• 溶解度：
  不溶于水

计算性质

• 辛醇/水分配系数(LogP)：
  0.54
• 重原子数：
  66
• 可旋转键数：
  18
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  421
• 氢给体数：
  10
• 氢受体数：
  24

安全信息

• 危险品标志：
  T
• 安全说明：
  S26,S36,S45,S53
• 危险类别码：
  R36/38,R25,R61
• WGK Germany：
  3
• 海关编码：
  29339980
• RTECS号：
  MA1225000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

用途

二水合氨甲嘌呤是一种细胞周期阻滞剂，可抑制DHFR和调节炎症。原发性中枢神经系统淋巴瘤的化疗。

文献信息

• LIPID NANOPARTICLE MRNA VACCINES
  申请人：CureVac AG

  公开号：US20200163878A1

  公开（公告）日：2020-05-28

  The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

  该发明涉及包含脂质纳米粒子的mRNA及其医药用途。本发明的脂质纳米粒子包括根据化学式(I)、(II)或(III)的阳离子脂质和/或根据化学式(IV)的PEG脂质，以及包含编码抗原肽或蛋白质的mRNA序列的mRNA化合物。该发明还涉及将所述脂质纳米粒子用作疫苗或药物，特别是针对流感或狂犬病疫苗接种。
• Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition
  申请人：THE KENNEDY INSTITUTE OF RHEUMATOLOGY

  公开号：EP1170017A1

  公开（公告）日：2002-01-09

  Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed are compositions comprising a TNFα antagonist and a VEGF antagonist. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.

  本研究公开了治疗和/或预防由 TNF 介导的疾病的方法。还公开了包含 TNFα 拮抗剂和血管内皮生长因子拮抗剂的组合物。TNF介导的疾病包括类风湿性关节炎、克罗恩病以及与移植相关的急性和慢性免疫疾病。
• Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
  申请人：The Kennedy Institute of Rheumatology

  公开号：US20020136723A1

  公开（公告）日：2002-09-26

  Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.

  本研究公开了治疗和/或预防由 TNF 介导的疾病的方法。还公开了一种包含甲氨蝶呤和抗肿瘤坏死因子抗体的组合物。TNF介导的疾病包括类风湿性关节炎、克罗恩病以及与移植相关的急性和慢性免疫疾病。
• Electrical devices and anti-scarring agents
  申请人：Hunter L. William

  公开号：US20050209665A1

  公开（公告）日：2005-09-22

  Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

  用于与组织接触的电气设备（如心律管理和神经刺激设备）与抗疤痕剂（如细胞周期抑制剂）结合使用，以抑制设备植入动物体内时可能产生的疤痕。
• TNFalpha antagonists and methotrexate in the treatment of TNF-mediated disease
  申请人：Feldmann Marc

  公开号：US20060099212A1

  公开（公告）日：2006-05-11

  Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.

  本研究公开了治疗和/或预防由 TNF 介导的疾病的方法。还公开了一种包含甲氨蝶呤和抗肿瘤坏死因子抗体的组合物。TNF介导的疾病包括类风湿性关节炎、克罗恩病以及与移植相关的急性和慢性免疫疾病。